CIBA Vision's Visudyne cleared in first market, Switzerland
CIBA Vision, the eye care unit of Novartis, has received its firstmarketing approval for Visudyne (verteporfin), a photodynamic therapy for age-related macular degeneration which was originally developed by QLT PhotoTherapeutics. The Swiss regulatory authorities approved Visudyne for the wet form of AMD, which is the leading cause of blindness in people aged over 50 in the western world. CIBA said it would be launching the product in Switzerland in the coming days.
Other regulatory applications are pending in the European Union, Canada, Norway, Iceland, Australia, New Zealand and the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze